Navigation Links
LSUHSC scientist awarded nearly $2 million to determine role of biofilms in common fungal infection
Date:2/6/2013

New Orleans, LA Mairi Noverr, PhD, Associate Professor in the Department of Prosthodontics at the LSU Health Sciences Center New Orleans School of Dentistry, has been awarded a $1.7 million grant over five years by the National Institute of Dental & Craniofacial Research of the National Institutes of Health to study the role of biofilms in infection and disease. This research will contribute to our understanding of how biofilms are involved in fungal disease development, leading to the discovery of new therapeutic targets.

Dr. Noverr, a microbiologist, is studying a model of dental stomatitis, a fungal infection affecting approximately 50-75% of otherwise healthy denture wearers, and C. albicans, the most common infection-causing yeast. C. albicans normally lives on the skin and mucous membranes without any problem. But its overgrowth can result in infection. C. albicans is the most common cause of denture stomatitis. C. albicans readily forms biofilm on denture materials; however, the role of biofilm formation in the disease development process of denture stomatitis is unknown. Biofilms are the sticky substances composed of microorganisms like yeasts, bacteria, etc. that form on and adhere to wet surfaces including teeth, dental prostheses, or implants. Dental plaque is an example of a biofilm.

The major goals of this grant are to determine the role of biofilm formation in Candida-associated denture stomatitis and determine how the immune response influences development of the disease.

"Information gathered in these studies can be applied to other Candida mucosal and device-related biofilm infections, which can cause systemic infection and significant illness and death," notes Dr. Noverr, who is also a member of the LSUHSC Center of Excellence in Oral Biology. "Because biofilms are not only resistant to antimicrobial drugs but also to immune defenses, this knowledge base can be used to develop novel immunotherapies that target biofilm growth."


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC research discovery provides therapeutic target for ALS
2. LSUHSCs Weiss chosen to help set national eye policy, research
3. LSUHSC research identifies new therapeutic target for Alzheimers disease
4. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
5. LSUHSC research finds treating stress prevented new MS brain lesions
6. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
7. Scientists turn toxic by-product into biofuel booster
8. Scientists find a key element of lupus, suggesting better drug targets
9. Scientists notch a win in war against antibiotic-resistant bacteria
10. Plant scientists at CSHL demonstrate new means of boosting maize yields
11. Listening to cells: Scientists probe human cells with high-frequency sound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: